



Substitute for form 1449A/PTO			<b>Complete if Known</b>		
<b>INFORMATION DISCLOSURE STATEMENT BY APPLICANT</b> (use as many sheets as necessary)			Application Number	10/786,720	
			Filing Date	February 26, 2004	
			First Named Inventor	O'TOOLE, et al.	
			Art Unit	Not Yet Assigned	
			Examiner Name	Not Yet Assigned	
Sheet	1	Of	3	Attorney Docket Number	031896-023000 (AM101331L)

U.S. PATENT DOCUMENTS					
Examiner Initials <sup>1</sup>	Cite No. <sup>1</sup>	U.S. Patent Document	Publication Date MM-DD-YYYY	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear
		Number - Kind Code <sup>2</sup> (if known)			
Ch		4,489,710	12-25-1984	Spitler	
		4,522,811	06-11-1985	Eppstein et al.	
		4,554,101	11-19-1985	Hopp	
		4,569,789	02-11-1986	Blattler et al.	
		4,625,014	11-25-1986	Senter et al.	
		4,638,045	01-20-1987	Kohn et al.	
		4,671,958	06-09-1987	Rodwell et al.	
		4,690,905	09-01-1987	Diamond et al.	
		4,751,180	06-14-1988	Cousens et al.	
		4,935,233	06-19-1990	Bell et al.	
		4,980,281	12-25-1990	Housey	
		5,266,464	11-30-1993	Housey	
		5,459,039	10-17-1995	Modrich et al.	
		5,688,635	11-18-1997	Parker et al.	
		5,877,007	03-02-1999	Housey	
		5,919,619	07-06-1999	Tullis	
		6,280,941	08-28-2001	Tsao et al.	
		2003/0148298	08-07-2003	O'Toole, M. et al	

FOREIGN PATENT DOCUMENTS						
Examiner Initials <sup>1</sup>	Cite No. <sup>1</sup>	Foreign Patent Document	Publication Date MM-DD-YYYY	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear	T <sup>6</sup>
		Country Code <sup>3</sup> Number <sup>4</sup> Kind Code <sup>5</sup> (if known)				
Ch		WO00/44895	10-26-2000	Pachuk et al.		
		WO00/63364	08-03-2000	Kreutzer et al.		
		WO01/29058	04-26-2001	Mello et al.		
		WO01/36646	05-25-2001	Zernicka-Goetz et al.		
		WO01/68836	09-20-2001	Beach et al.		
		WO01/70949	09-27-2001	Graham et al.		
		WO01/75164	10-11-2001	Tuschl		
		WO01/92513	12-06-2001	Arndt et al.		
		WO89/10134	11-02-1989	Pardridge et al.		
		WO99/14346	03-25-1999	Woelf		
		WO04/036221	04-29-2004	O'Toole et al.		
Examiner Signature	Chen			Date Considered	8/16/06	

\*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

<sup>1</sup> Applicant's unique citation designation number (optional). <sup>2</sup> See Kinds Codes of USPTO Patent Documents at [www.uspto.gov](http://www.uspto.gov) or MPEP 901.04. <sup>3</sup> Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). <sup>4</sup> For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. <sup>5</sup> Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST.16 if possible. <sup>6</sup> Applicant is to place a check mark here if English language Translation is attached.

<sup>1</sup> Applicant's unique citation designation number (optional). <sup>2</sup> Applicant is to place a check mark here if English language Translation is attached.

Substitute for form 1449A/PTO <b>INFORMATION DISCLOSURE STATEMENT BY APPLICANT</b> <i>(use as many sheets as necessary)</i>				<b>Complete if Known</b>	
Sheet		2	Of	3	Application Number 10/786,720
					Filing Date February 26, 2004
					First Named Inventor O'TOOLE, et al.
					Art Unit Not Yet Assigned
					Examiner Name Not Yet Assigned
					Attorney Docket Number 031896-023000 (AM101331L)
OTHER PRIOR ART – NON PATENT LITERATURE DOCUMENTS					
Examiner Initials <sup>5</sup>	Cite No. <sup>1</sup>	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.			T <sup>2</sup>
<div style="position: relative; height: 100px;"> <span style="position: absolute; left: -20px; top: 50%; transform: translateY(-50%); font-size: 2em;">C</span> </div>		DELAGRAVE <i>et al.</i> , <i>Protein Engineering</i> , 6:327-331, 1993			
		FRAMPTON <i>et al.</i> , <i>Rheumatology</i> , 39:1114-1120, 2000			
		GOSSEN <i>et al.</i> , <i>Science</i> , 268: 1766-1769, 1995			
		HILL <i>et al.</i> , <i>Genome Biol.</i> , 2(12):1-13, 2001			
		KEEN <i>et al.</i> , <i>Trends Genet.</i> , 75, 1991			
		LAM, <i>Anticancer Drug Des.</i> , 12:145-167, 1997			
		MARATEA <i>et al.</i> , <i>Gene</i> , 40:39-46, 1985			
		MURPHY <i>et al.</i> , <i>Proc. Natl. Acad. Sci. USA</i> , 83:8258-8262, 1986;			
		MYERS <i>et al.</i> , <i>Science</i> , 230: 1242-1246, 1985			
		ADACHI, <i>Cancer Res.</i> , 56:1751-1755, 1996			
		DUAN, <i>FEBS Lett.</i> , 499:127-132, 2001			
		HAMMOND <i>et al.</i> , <i>J. Immunol.</i> , 161:3282-91, 1998			
		HECKENLIVELY, <i>Arch. Ophthalmol.</i> , 118:1525-33, 2000			
		LAGAUDRIERE-GESBERT <i>et al.</i> , <i>J. Immunol.</i> , 158:2790-2797, 1997			
		LEBEL-BINAY <i>et al.</i> , <i>J. Immunol.</i> , 155:101-110, 1995			
	LOCKHART <i>et al.</i> , <i>Nature Biotechnology</i> , 14:1675-80, 1996				
	MAEDA <i>et al.</i> , <i>Eur. J. Immunol.</i> , 32:2300-2307, 2002				
	ROTH <i>et al.</i> , <i>Oncogene</i> , 19:4210-4220, 2000				
	SUI <i>et al.</i> , <i>Proc. Natl. Acad. Sci. USA</i> 99: 5515-5520, 2002				
	XU <i>et al.</i> , <i>Biochem. Biophys. Res. Commun.</i> , 292:944-950, 2002				
	XU <i>et al.</i> , <i>J. Biol. Chem.</i> , 274:31286-31290, 1999				
	YOSHINO <i>et al.</i> , <i>Mech. Dev.</i> , 192:45-55, 2001				
Examiner Signature				Date Considered	8/16/06

\*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

<sup>1</sup> Applicant's unique citation designation number (optional). <sup>2</sup> See Kinds Codes of USPTO Patent Documents at [www.uspto.gov](http://www.uspto.gov) or MPEP 901.04. <sup>3</sup> Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). <sup>4</sup> For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. <sup>5</sup> Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST.16 if possible. <sup>6</sup> Applicant is to place a check mark here if English language Translation is attached.

<sup>1</sup> Applicant's unique citation designation number (optional). <sup>2</sup> Applicant is to place a check mark here if English language Translation is attached.

Substitute for form 1449A/PTO <b>INFORMATION DISCLOSURE STATEMENT BY APPLICANT</b> <i>(use as many sheets as necessary)</i>				<i>Complete if Known</i>		
				Application Number		10/786,720
				Filing Date		February 26, 2004
				First Named Inventor		O'TOOLE, et al.
				Art Unit		Not Yet Assigned
Examiner Name		Not Yet Assigned				
Sheet	3	Of	3	Attorney Docket Number		031896-023000 (AM101331L)


OTHER PRIOR ART - NON PATENT LITERATURE DOCUMENTS			
Examiner Initials	Cite No. <sup>1</sup>	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	T <sup>2</sup>
Cm		BAZHIN <i>et al.</i> , <i>Lung Cancer</i> , 34:99-104, 2001	
		NEEDLEMAN and WUNSCH, <i>J. Mol. Biol.</i> , 48:444-453, 1970)	
		NO <i>et al.</i> , <i>Proc. Natl. Acad. Sci., USA</i> , 93: 3346-3351, 1996	
		ROSENBAUM and REISSNER, <i>Biophys. Chem.</i> , 26:235-246, 1987	
		SAIKI <i>et al.</i> , <i>Proc Natl. Acad. Sci. USA</i> , 86:6230, 1989	
		THEOFILOPOULUS, <i>Immunology Today</i> , 15:150-58, 1995	
		WANG <i>et al.</i> , <i>Nat. Biotech.</i> , 15: 239-243, 1997	
		YE <i>et al.</i> , <i>Science</i> , 283 88-91, 1999	
		ZUCKERMANN <i>et al.</i> , <i>J. Med. Chem.</i> , 37: 2678-85, 1994	
		International Application No. PCT/US2004/005655 International Search Report dated November 8, 2004	
✓		ROZZO, STEPHEN J. <i>et al.</i> , "Evidence for an interferon-inducible gene, Ifi202, in the susceptibility to systemic lupus," <i>Immunity</i> , 15(3): 435-443, 2001	
		MOSER, KATHY L. <i>et al.</i> , "The use of microarrays to study autoimmunity," <i>Journal of Investigative Dermatology Symposium Proceedings</i> , 9(1):18-22, 2004	
		BENNETT, LYNDIA <i>et al.</i> , "Interferon and granulopoiesis signatures in systemic lupus erythematosus blood," <i>Journal of Experimental Medicine</i> , 197(6):711-723, 2003	

Examiner Signature	<i>Cm</i>	Date Considered	8/16/06
--------------------	-----------	-----------------	---------

\*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

<sup>1</sup> Applicant's unique citation designation number (optional). <sup>2</sup> See Kinds Codes of USPTO Patent Documents at [www.uspto.gov](http://www.uspto.gov) or MPEP 901.04. <sup>3</sup> Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). <sup>4</sup> For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. <sup>5</sup> Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST.16 if possible. <sup>6</sup> Applicant is to place a check mark here if English language Translation is attached.

<sup>1</sup> Applicant's unique citation designation number (optional). <sup>2</sup> Applicant is to place a check mark here if English language Translation is attached.



Substitute for form 1449		<b>Complete If Known</b>	
<b>INFORMATION DISCLOSURE STATEMENT BY APPLICANT</b> (use as many sheets as necessary)		Application Number	10/786,720
		Filing Date	February 26, 2004
		First Named Inventor	Margot Mary O'TOOLE <i>et al.</i>
		Art Unit	1634
		Examiner Name	Carla J. Myers
Sheet 1 of 3	Attorney Docket Number	031896-023000 (AM101329)	

U.S. PATENT DOCUMENTS					
Examiner Initials <sup>*</sup>	Cite No. <sup>1</sup>	U.S. Patent Document	Publication Date MM-DD-YYYY	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear
		Number - Kind Code <sup>2</sup> (if known)			
CM		U.S. - 6,506,559	01/14/2003	FIRE <i>et al.</i>	
CM		U.S. - 5,498,531	03/12/1996	JARRELL	

Examiner Signature	Date Considered
--------------------	-----------------

FOREIGN PATENT DOCUMENTS						
Examiner Initials <sup>*</sup>	Cite No. <sup>1</sup>	Foreign Patent Document	Publication Date MM-DD-YYYY	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear	T <sup>4</sup>
		Country Code <sup>3</sup> Number <sup>2</sup> Kind Code <sup>3</sup> (if known)				
CM		WO - 1997/07668 A1	03/06/1997	CAMPBELL <i>et al.</i>		
CM		WO - 1997/07669 A1	03/06/1997	CAMPBELL <i>et al.</i>		

Examiner Signature	Date Considered
--------------------	-----------------

OTHER PRIOR ART - NON PATENT LITERATURE DOCUMENTS			
Examiner Initials <sup>*</sup>	Cite No. <sup>1</sup>	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	T <sup>2</sup>
CM		SUN, X.-Z. <i>et al.</i> , An immunohistochemical study of radial glial cells in the mouse brain prenatally exposed to gamma-irradiation, <i>J. Neuropathol Exp Neurol</i> , 56(12):1339-1348, 1997	
		KADOMATSU, K. <i>et al.</i> , Midkine induces the transformation of NIH3T3 cells, <i>Br J Cancer</i> , 75(3):354-359, 1997	
		CHOUDHURI, R. <i>et al.</i> , An angiogenic role for the neurokines midkine and pleiotrophin in tumorigenesis, <i>Cancer Res.</i> , 57(9):1814-1819, 1997	
		TAKEI, Y. <i>et al.</i> , Antisense oligodeoxynucleotide targeted to Midkine, a heparin-binding growth factor, suppresses tumorigenicity of mouse rectal carcinoma cells, <i>Cancer Res.</i> , 61(23):8486-8491, 2001	
		TAKEI, Y. <i>et al.</i> , 5',3'-inverted thymidine-modified antisense oligodeoxynucleotide targeting midkine. Its design and application for cancer therapy, <i>J. Biol. Chem.</i> , 277(26):23800-23806, 2002	
		INUI, T. <i>et al.</i> , Solution synthesis of human midkine, a novel heparin-binding neurotrophic factor consisting of 121 amino acid residues with five disulphide bonds, <i>J. Peptide Sci.</i> , 2(1):28-39, 1996	
		MURAMATSU, H. <i>et al.</i> , Localization of heparin-binding, neurite outgrowth and antigenic regions in midkine molecule, <i>Biochem. Biophys. Res. Commun.</i> , 203(2):1131-1139, 1994	
CM		ASAI, T. <i>et al.</i> , Identification of heparin-binding sites in midkine and their role in neurite-promotion, <i>Biochem. Biophys. Res. Commun.</i> , 236(1):66-70, 1997	

Examiner Signature	Carla Myers	Date Considered	8/16/06
--------------------	-------------	-----------------	---------

\*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

<sup>1</sup> Applicant's unique citation designation number (optional). <sup>2</sup> See Kinds Codes of USPTO Patent Documents at www.uspto.gov or MPEP 901.04. <sup>3</sup> Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). <sup>4</sup> For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. <sup>5</sup> Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST.16 if possible. <sup>6</sup> Applicant is to place a check mark here if English language Translation is attached.

Substitute for form 1449A/PTO		<b>Complete if Known</b>	
<b>INFORMATION DISCLOSURE STATEMENT BY APPLICANT</b> <i>(use as many sheets as necessary)</i>		Application Number	10/786,720
		Filing Date	February 26, 2004
		First Named Inventor	Margot O'TOOLE <i>et al.</i>
		Art Unit	1634
		Examiner Name	Carla J. Myers
		Attorney Docket Number	031896-023000 (AM101329)
Sheet	2	of	3

OTHER PRIOR ART - NON PATENT LITERATURE DOCUMENTS			
Examiner Initials <sup>*</sup>	Cite No. <sup>1</sup>	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	T <sup>2</sup>
CR		KANEDA, N. <i>et al.</i> , Structural characteristics of heparin-line domain required for interaction of midkine with embryonic neurons, <i>Biochem. Biophys. Res. Commun.</i> , 220(1):108-112, 1996	
		PEDRAZA, C. <i>et al.</i> , A retinoic acid-responsive element in human midkine gene, <i>J. Biochem. (Tokyo)</i> , 117(4):845-849, 1995	
		AHMED, K. M. <i>et al.</i> , Association of an intronic polymorphism in the midkine (MK) gene with human sporadic colorectal cancer, <i>Cancer Lett.</i> , 180(2):159-63, 2002	
		AHMED, K. M. <i>et al.</i> , Genetic variations of the midkine (MK) gene in human sporadic colorectal and gastric cancers, <i>Int. J. Mol. Med.</i> , 6(3):281-287, 2000	
		URIOS, P. <i>et al.</i> , Molecular cloning of RI-HB, a heparin binding protein regulated by retinoic acid, <i>Biochem. Biophys. Res. Commun.</i> , 175(2):617-627, 1991	
		NAIR, S. M. <i>et al.</i> , Expression of HNK-1 carbohydrate and its binding protein, SBP-1, in apposing cell surfaces in cerebral cortex and cerebellum, <i>Neuroscience</i> , 85(30):759-771, 1998	
		LEE, N. S. <i>et al.</i> , Expression of small interfering RNAs targeted against HIV-1 rev transcripts in human cells, <i>Nat. Biotechnol.</i> , 20(5):500-505, 2002	
		ALTSCHUL, S. F. <i>et al.</i> , Gapped BLAST and PSI-BLAST: a new generation of protein database search programs, <i>Nucleic Acids Res.</i> , 25(17):3389-3402, 1997	
		GUATELLI <i>et al.</i> , Isothermal, in vitro amplification of nucleic acids by a multienzyme reaction modeled after retroviral replication, <i>Proc. Natl. Acad. Sci. USA</i> , 87(5):1874-1878, 1990. Erratum in: <i>Proc. Natl. Acad. Sci. USA</i> , 87(19):7797, 1990	
		KWOH, D. Y. <i>et al.</i> , Transcription-based amplification system and detection of amplified human immunodeficiency virus type 1 with a bead-based sandwich hybridization format, <i>Proc. Natl. Acad. Sci. USA</i> , 86(4):1173-1177, 1989	
		LIZARDI, P. M. <i>et al.</i> , Exponential amplification of recombinant-RNA hybridization probes, <i>Bio-Technology</i> , 6:1197-1202, 1988	
		O'GORMAN, S. <i>et al.</i> , Recombinase-mediated gene activation and site-specific integration in mammalian cells, <i>Science</i> , 251(4999):1351-1355, 1991	
		WILMUT, I. <i>et al.</i> , Viable offspring derived from fetal and adult mammalian cells, <i>Nature</i> 385(6619):810-813, 1997. Erratum in: <i>Nature</i> , 386(6621):200, 1997	
		MISHIMA, K. <i>et al.</i> , Increased expression of midkine during the progression of human astrocytomas, <i>Neurosci. Lett.</i> , 233(1):29-32, 1997	
		TSUTSUI, J. <i>et al.</i> , A new family of heparin-binding growth/differentiation factors: increased midkine expression in Wilms' tumor and other human carcinomas, <i>Cancer Res.</i> , 53(6):1281-1285, 1993	
		KUROSAWA, N. <i>et al.</i> , Midkine binds specifically to sulfatide the role of sulfatide in cell attachment to midkine-coated surfaces, <i>Eur. J. Biochem.</i> , 267(2):344-351, 2000	
		ZOU, K. <i>et al.</i> , A heparin-binding growth factor, midkine, binds to a chondroitin sulfate proteoglycan, PG-M/versican, <i>Eur. J. Biochem.</i> , 267(13):4046-4053, 2000	

Examiner Signature	<i>Chen</i>	Date Considered	8/16/06
--------------------	-------------	-----------------	---------

\*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

<sup>1</sup> Applicant's unique citation designation number (optional). <sup>2</sup> See Kinds Codes of USPTO Patent Documents at [www.uspto.gov](http://www.uspto.gov) or MPEP 901.04. <sup>3</sup> Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). <sup>4</sup> For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. <sup>5</sup> Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST.16 if possible. <sup>6</sup> Applicant is to place a check mark here if English language Translation is attached.

Substitute for form 1449A/PTO				<b>Complete if Known</b>	
<b>INFORMATION DISCLOSURE STATEMENT BY APPLICANT</b> <i>(use as many sheets as necessary)</i>				Application Number	10/786,720
				Filing Date	February 26, 2004
				First Named Inventor	Margot O'TOOLE <i>et al.</i>
				Art Unit	1634
				Examiner Name	Carla J. Myers
Sheet	3	of	3	Attorney Docket Number	031896-023000 (AM101329)

OTHER PRIOR ART – NON PATENT LITERATURE DOCUMENTS			
Examiner Initials*	Cite No. <sup>1</sup>	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	T <sup>2</sup>
CM		SAID, E. A. <i>et al.</i> , The anti-HIV cytokine midkine binds the cell surface-expressed nucleolin as a low affinity receptor, <i>J. Biol. Chem.</i> , 277(40):37492-37502, 2002	
		STOICA, G. E. <i>et al.</i> , Midkine binds to anaplastic lymphoma kinase (ALK) and acts as a growth factor for different cell types, <i>J. Biol. Chem.</i> , 277(39):35990-35998, 2002	
		IKEDA, S. <i>et al.</i> , Effects of midkine during <i>in vitro</i> maturation of bovine oocytes on subsequent developmental competence, <i>Biol. Reprod.</i> , 63(4):1067-1074, 2000	
		KATO, M. <i>et al.</i> , Increased midkine expression in intrahepatic cholangiocarcinoma: immunohistochemical and <i>in situ</i> hybridization analyses, <i>Liver</i> , 20(3):216-221, 2000	
		International Application No. PCT/US2003/33054, International Search Report mailed August 3, 2004, 3 pages	
		IWASAKI, W. <i>et al.</i> , Solution structure of midkine, a new heparin-binding growth factor, <i>EMBO J.</i> , 16(23):6936-6946, 1997	
		MYERS, E.W. and MILLER, W., Optical alignments in linear space, <i>CABIOS</i> , 4(1):11-17, 1988	
		TSUTSUI, J. <i>et al.</i> , A new family of heparin-binding factors: strong conservation of midkine (MK) sequences between the human and the mouse, <i>Biochem. Biophys. Res. Commun.</i> , 176(2):792-797, 1991	

Examiner Signature	<i>Oxeyn</i>	Date Considered	8/16/04
--------------------	--------------	-----------------	---------

\*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

<sup>1</sup> Applicant's unique citation designation number (optional). <sup>2</sup> See Kinds Codes of USPTO Patent Documents at [www.uspto.gov](http://www.uspto.gov) or MPEP 901.04. <sup>3</sup> Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). <sup>4</sup> For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. <sup>5</sup> Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST.16 if possible. <sup>6</sup> Applicant is to place a check mark here if English language Translation is attached.